Molecular and cellular heterogeneity in breast cancer: Challenges for personalized medicine

American Journal of Pathology

Volumn 183, Issue 4, 2013, Pages 1113-1124

  Rivenbark, Ashley G ^a   O'Connor, Siobhan M ^a   Coleman, William B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LUMINAL A; LUMINAL B; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL HETEROGENEITY; DISEASE CLASSIFICATION; EPIGENETICS; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMANS; INDIVIDUALIZED MEDICINE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 84884559633     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.08.002     Document Type: Review

References (96)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics [Erratum appeared in CA Cancer J Clin 2011, 61:134] CA Cancer J Clin 61 2011 69 90
3. K. Kurose, S. Hoshaw-Woodard, A. Adeyinka, S. Lemeshow, P.H. Watson, and C. Eng Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions Hum Mol Genet 10 2001 1907 1913
4. T. Wu, Y. Li, L. Gong, J.G. Lu, X.L. Du, W.D. Zhang, X.L. He, and J.Q. Wang Multi-step process of human breast carcinogenesis: a role for BRCA1, BECN1, CCND1, PTEN and UVRAG Mol Med Rep 5 2012 305 312
5. J.L. Kelsey, and G.S. Berkowitz Breast cancer epidemiology Cancer Res 48 1988 5615 5623
6. P. van der Groep, E. van der Wall, and P.J. van Diest Pathology of hereditary breast cancer Cell Oncol (Dordr) 34 2011 71 88
7. L. Da Silva, and S.R. Lakhani Pathology of hereditary breast cancer Mod Pathol 23 Suppl 2 2010 S46 S51
8. S.R. Wellings, and H.M. Jensen On the origin and progression of ductal carcinoma in the human breast J Natl Cancer Inst 50 1973 1111 1118
9. A.G. Rivenbark, and W.B. Coleman Field cancerization in mammary carcinogenesis-implications for prevention and treatment of breast cancer Exp Mol Pathol 93 2012 391 398
10. B.A. Virnig, T.M. Tuttle, T. Shamliyan, and R.L. Kane Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes J Natl Cancer Inst 102 2010 170 178
11. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 [Erratum appeared in CA Cancer J Clin 2011, 61:133-134] CA Cancer J Clin 60 2010 277 300
12. C.J. Allegra, D.R. Aberle, P. Ganschow, S.M. Hahn, C.N. Lee, S. Millon-Underwood, M.C. Pike, S.D. Reed, A.F. Saftlas, S.A. Scarvalone, A.M. Schwartz, C. Slomski, G. Yothers, and R. Zon National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ September 22-24, 2009 J Natl Cancer Inst 102 2010 161 169
13. D.C. Allred Ductal carcinoma in situ: terminology, classification, and natural history J Natl Cancer Inst Monogr 2010 2010 134 138
14. C.M. Perou, S.S. Jeffrey, M. van de Rijn, C.A. Rees, M.B. Eisen, D.T. Ross, A. Pergamenschikov, C.F. Williams, S.X. Zhu, J.C. Lee, D. Lashkari, D. Shalon, P.O. Brown, and D. Botstein Distinctive gene expression patterns in human mammary epithelial cells and breast cancers Proc Natl Acad Sci USA 96 1999 9212 9217
15. C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lønning, A.L. Børresen-Dale, P.O. Brown, and D. Botstein Molecular portraits of human breast tumours Nature 406 2000 747 752
16. T. Sørlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, T. Thorsen, H. Quist, J.C. Matese, P.O. Brown, D. Botstein, P.E. Lønning, and A.L. Børresen-Dale Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 2001 10869 10874
17. T. Sørlie Molecular portraits of breast cancer: tumour subtypes as distinct disease entities Eur J Cancer 40 2004 2667 2675
18. C. Sotiriou, C. Desmedt, V. Durbecq, L. Dal Lago, M. Lacroix, F. Cardoso, and M. Piccart Genomic and molecular classification of breast cancer. Molecular Oncology of Breast Cancer J.S. Ross, G.N. Hortobagyi, 2005 Jones & Bartlett Sudbury, MA 81 95
19. D.J. Dabbs, M. Chivukula, G. Carter, and R. Bhargava Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile Mod Pathol 19 2006 1506 1511
20. B.B. Bryan, S.J. Schnitt, and L.C. Collins Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer Mod Pathol 19 2006 617 621
21. J. Hannemann, A. Velds, J.B. Halfwerk, B. Kreike, J.L. Peterse, and M.J. van de Vijver Classification of ductal carcinoma in situ by gene expression profiling Breast Cancer Res 8 2006 R61
22. C.A. Livasy, C.M. Perou, G. Karaca, D.W. Cowan, D. Maia, S. Jackson, C.K. Tse, S. Nyante, and R.C. Millikan Identification of a basal-like subtype of breast ductal carcinoma in situ Hum Pathol 38 2007 197 204
23. R.M. Tamimi, H.J. Baer, J. Marotti, M. Galan, L. Galaburda, Y. Fu, A.C. Deitz, J.L. Connolly, S.J. Schnitt, G.A. Colditz, and L.C. Collins Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer Breast Cancer Res 10 2008 R67
24. D.C. Allred, Y. Wu, S. Mao, I.D. Nagtegaal, S. Lee, C.M. Perou, S.K. Mohsin, P. O'Connell, A. Tsimelzon, and D. Medina Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution Clin Cancer Res 14 2008 370 378
25. D.E. Newburger, D. Kashef-Haghighi, Z. Weng, R. Salari, R.T. Sweeney, A.L. Brunner, S.X. Zhu, X. Guo, S. Varma, M.L. Troxell, R.B. West, S. Batzoglou, and A. Sidow Genome evolution during progression to breast cancer Genome Res 23 2013 1097 1108
26. K. Polyak Breast cancer: origins and evolution J Clin Invest 117 2007 3155 3163
27. P.P. Rosen The pathological classification of human mammary carcinoma: past, present and future Ann Clin Lab Sci 9 1979 144 156
28. L.J. van Bogaert Recent progress in the histological typing of human breast tumours Diagn Histopathol 4 1981 349 353
29. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
30. M.E. Hammond, D.F. Hayes, M. Dowsett, D.C. Allred, K.L. Hagerty, S. Badve, P.L. Fitzgibbons, G. Francis, N.S. Goldstein, M. Hayes, D.G. Hicks, S. Lester, R. Love, P.B. Mangu, L. McShane, K. Miller, C.K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J.N. Schwartz, F.C. Sweep, S. Taube, E.E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R.B. Williams, J.L. Wittliff, and A.C. Wolff American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [Erratum appeared in J Clin Oncol 2010, 28:3543] J Clin Oncol 28 2010 2784 2795
31. A.C. Wolff, M.E. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Allred, R.J. Cote, M. Dowsett, P.L. Fitzgibbons, W.M. Hanna, A. Langer, L.M. McShane, S. Paik, M.D. Pegram, E.A. Perez, M.F. Press, A. Rhodes, C. Sturgeon, S.E. Taube, R. Tubbs, G.H. Vance, M. van de Vijver, T.M. Wheeler, D.F. Hayes American Society of Clinical Oncology; College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
32. N. Patani, L.A. Martin, and M. Dowsett Biomarkers for the clinical management of breast cancer: international perspective Int J Cancer 133 2013 1 13
33. W.F. Anderson, N. Chatterjee, W.B. Ershler, and O.W. Brawley Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database Breast Cancer Res Treat 76 2002 27 36
34. X. Cui, R. Schiff, G. Arpino, C.K. Osborne, and A.V. Lee Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 2005 7721 7735
35. E.A. Rakha, M.E. El-Sayed, A.R. Green, E.C. Paish, D.G. Powe, J. Gee, R.I. Nicholson, A.H. Lee, J.F. Robertson, and I.O. Ellis Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype J Clin Oncol 25 2007 4772 4778
36. K.B. Horwitz, Y. Koseki, and W.L. McGuire Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen Endocrinology 103 1978 1742 1751
37. M. Lee, C.S. Lee, and P.H. Tan Hormone receptor expression in breast cancer: postanalytical issues J Clin Pathol 66 2013 478 484
38. T. Sørlie, R. Tibshirani, J. Parker, T. Hastie, J.S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C.M. Perou, P.E. Lønning, P.O. Brown, A.L. Børresen-Dale, and D. Botstein Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 2003 8418 8423
39. C. Sotiriou, S.Y. Neo, L.M. McShane, E.L. Korn, P.M. Long, A. Jazaeri, P. Martiat, S.B. Fox, A.L. Harris, and E.T. Liu Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 2003 10393 10398
40. C. Sotiriou, T.J. Powles, M. Dowsett, A.A. Jazaeri, A.L. Feldman, L. Assersohn, C. Gadisetti, S.K. Libutti, and E.T. Liu Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer Breast Cancer Res 4 2002 R3
41. M.J. van de Vijver, Y.D. He, L.J. van't Veer, H. Dai, A.A. Hart, D.W. Voskuil, G.J. Schreiber, J.L. Peterse, C. Roberts, M.J. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, T. van der Velde, H. Bartelink, S. Rodenhuis, E.T. Rutgers, S.H. Friend, and R. Bernards A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009
42. L.J. van 't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, H.L. Peterse, K. van der Kooy, M.J. Marton, A.T. Witteveen, G.J. Schreiber, R.M. Kerkhoven, C. Roberts, P.S. Linsley, R. Bernards, and S.H. Friend Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
43. J.S. Parker, M. Mullins, M.C. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, J.F. Quackenbush, I.J. Stijleman, J. Palazzo, J.S. Marron, A.B. Nobel, E. Mardis, T.O. Nielsen, M.J. Ellis, C.M. Perou, and P.S. Bernard Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 2009 1160 1167
44. A. Prat, and C.M. Perou Deconstructing the molecular portraits of breast cancer Mol Oncol 5 2011 5 23
45. S. Loi, B. Haibe-Kains, C. Desmedt, F. Lallemand, A.M. Tutt, C. Gillet, P. Ellis, A. Harris, J. Bergh, J.A. Foekens, J.G. Klijn, D. Larsimont, M. Buyse, G. Bontempi, M. Delorenzi, M.J. Piccart, and C. Sotiriou Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade [Erratum appeared in J Clin Oncol 2007, 25:3790] J Clin Oncol 25 2007 1239 1246
46. M.C. Cheang, S.K. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, M. Watson, S. Davies, P.S. Bernard, J.S. Parker, C.M. Perou, M.J. Ellis, and T.O. Nielsen Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 2009 736 750
47. J.D. Brenton, L.A. Carey, A.A. Ahmed, and C. Caldas Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23 2005 7350 7360
48. J. Baselga, E.A. Perez, T. Pienkowski, and R. Bell Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer Oncologist 11 Suppl 1 2006 4 12
49. L.J. Tafe, and G.J. Tsongalis The human epidermal growth factor receptor 2 (HER2) Clin Chem Lab Med 50 2012 23 30
50. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
51. H. Mukai Treatment strategy for HER2-positive breast cancer Int J Clin Oncol 15 2010 335 340
52. L.A. Carey Breast cancer: HER2-a good addiction Nat Rev Clin Oncol 9 2012 196 197
53. A.D. Elias Triple-negative breast cancer: a short review Am J Clin Oncol 33 2010 637 645
54. R.H. Wetzels, R. Holland, U.J. van Haelst, E.B. Lane, I.M. Leigh, and F.C. Ramaekers Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast Am J Pathol 134 1989 571 579
55. T.O. Nielsen, F.D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler, L.A. Akslen, J. Ragaz, A.M. Gown, C.B. Gilks, M. van de Rijn, and C.M. Perou Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 2004 5367 5374
56. R.C. Millikan, B. Newman, C.K. Tse, P.G. Moorman, K. Conway, L.G. Dressler, L.V. Smith, M.H. Labbok, J. Geradts, J.T. Bensen, S. Jackson, S. Nyante, C. Livasy, L. Carey, H.S. Earp, and C.M. Perou Epidemiology of basal-like breast cancer Breast Cancer Res Treat 109 2008 123 139
57. L.A. Carey, C.M. Perou, C.A. Livasy, L.G. Dressler, D. Cowan, K. Conway, G. Karaca, M.A. Troester, C.K. Tse, S. Edmiston, S.L. Deming, J. Geradts, M.C. Cheang, T.O. Nielsen, P.G. Moorman, H.S. Earp, and R.C. Millikan Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2006 2492 2502
58. R. Rouzier, C.M. Perou, W.F. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K.R. Hess, J. Stec, M. Ayers, P. Wagner, P. Morandi, C. Fan, I. Rabiul, J.S. Ross, G.N. Hortobagyi, and L. Pusztai Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 2005 5678 5685
59. L.A. Carey, E.C. Dees, L. Sawyer, L. Gatti, D.T. Moore, F. Collichio, D.W. Ollila, C.I. Sartor, M.L. Graham, and C.M. Perou The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2007 2329 2334
60. A. Prat, J.S. Parker, O. Karginova, C. Fan, C. Livasy, J.I. Herschkowitz, X. He, and C.M. Perou Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Res 12 2010 R68
61. M.J. Ellis, and C.M. Perou The genomic landscape of breast cancer as a therapeutic roadmap Cancer Discov 3 2013 27 34
62. A. Prat, M.J. Ellis, and C.M. Perou Practical implications of gene-expression-based assays for breast oncologists Nat Rev Clin Oncol 9 2012 48 57
63. J.C. Harrell, A. Prat, J.S. Parker, C. Fan, X. He, L. Carey, C. Anders, M. Ewend, and C.M. Perou Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse Breast Cancer Res Treat 132 2012 523 535
64. H. Mukai Targeted therapy in breast cancer: current status and future directions Jpn J Clin Oncol 40 2010 711 716
65. E.A. Rakha Pitfalls in outcome prediction of breast cancer J Clin Pathol 66 2013 458 464
66. S. Paik Is gene array testing to be considered routine now? Breast 20 Suppl 3 2011 S87 S91
67. A.M. Glas, A. Floore, L.J. Delahaye, A.T. Witteveen, R.C. Pover, N. Bakx, J.S. Lahti-Domenici, T.J. Bruinsma, M.O. Warmoes, R. Bernards, L.F. Wessels, and L.J. Van't Veer Converting a breast cancer microarray signature into a high-throughput diagnostic test BMC Genomics 7 2006 278
68. M. Buyse, S. Loi, L. van't Veer, G. Viale, M. Delorenzi, A.M. Glas, M.S. d'Assignies, J. Bergh, R. Lidereau, P. Ellis, A. Harris, J. Bogaerts, P. Therasse, A. Floore, M. Amakrane, F. Piette, E. Rutgers, C. Sotiriou, F. Cardoso, M.J. Piccart TRANSBIG Consortium Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 98 2006 1183 1192
69. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, F.L. Baehner, M.G. Walker, D. Watson, T. Park, W. Hiller, E.R. Fisher, D.L. Wickerham, J. Bryant, and N. Wolmark A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826
70. M. Cronin, C. Sangli, M.L. Liu, M. Pho, D. Dutta, A. Nguyen, J. Jeong, J. Wu, K.C. Langone, and D. Watson Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer Clin Chem 53 2007 1084 1091
71. V. Kaklamani A genetic signature can predict prognosis and response to therapy in breast cancer: oncotype DX Expert Rev Mol Diagn 6 2006 803 809
72. A. Prat, J.S. Parker, C. Fan, M.C. Cheang, L.D. Miller, J. Bergh, S.K. Chia, P.S. Bernard, T.O. Nielsen, M.J. Ellis, L.A. Carey, and C.M. Perou Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen Ann Oncol 23 2012 2866 2873
73. S.J. Potts, J.S. Krueger, N.D. Landis, D.A. Eberhard, G.D. Young, S.C. Schmechel, and H. Lange Evaluating tumor heterogeneity in immunohistochemistry- stained breast cancer tissue Lab Invest 92 2012 1342 1357
74. L.T. Greer, M. Rosman, W.C. Mylander, J. Hooke, A. Kovatich, K. Sawyer, R.R. Buras, C.D. Shriver, and L. Tafra Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J Am Coll Surg 216 2013 239 251
75. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2003 2042 2054
76. S. Baylin DNA methylation and epigenetic mechanisms of carcinogenesis Dev Biol (Basel) 106 2001 85 87
77. S.B. Baylin, J.G. Herman, J.R. Graff, P.M. Vertino, and J.P. Issa Alterations in DNA methylation: a fundamental aspect of neoplasia Adv Cancer Res 72 1998 141 196
78. Y.K. Bae, A. Brown, E. Garrett, D. Bornman, M.J. Fackler, S. Sukumar, J.G. Herman, and E. Gabrielson Hypermethylation in histologically distinct classes of breast cancer Clin Cancer Res 10 2004 5998 6005
79. F.E. Domann, J.C. Rice, M.J. Hendrix, and B.W. Futscher Epigenetic silencing of maspin gene expression in human breast cancers Int J Cancer 85 2000 805 810
80. M.J. Fackler, M. McVeigh, E. Evron, E. Garrett, J. Mehrotra, K. Polyak, S. Sukumar, and P. Argani DNA methylation of RASSF1A, HIN-1, RAR-beta, cyclin D2 and Twist in in situ and invasive lobular breast carcinoma Int J Cancer 107 2003 970 975
81. T.H. Huang, M.R. Perry, and D.E. Laux Methylation profiling of CpG islands in human breast cancer cells Hum Mol Genet 8 1999 459 470
82. M.S. Jhaveri, and C.S. Morrow Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells Gene 210 1998 1 7
83. A.G. Rivenbark, W.D. Jones, J.D. Risher, and W.B. Coleman DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells Epigenetics 1 2006 32 44
84. A.G. Rivenbark, C.A. Livasy, C.E. Boyd, D. Keppler, and W.B. Coleman Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions Exp Mol Pathol 83 2007 188 197
85. A.G. Rivenbark, W.D. Jones, and W.B. Coleman DNA methylation-dependent silencing of CST6 in human breast cancer cell lines Lab Invest 86 2006 1233 1242
86. X. Yang, L. Yan, and N.E. Davidson DNA methylation in breast cancer Endocr Relat Cancer 8 2001 115 127
87. P.S. Yan, H. Shi, F. Rahmatpanah, T.H. Hsiau, A.H. Hsiau, Y.W. Leu, J.C. Liu, and T.H. Huang Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer Cancer Res 63 2003 6178 6186
88. R. Dammann, G. Yang, and G.P. Pfeifer Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers Cancer Res 61 2001 3105 3109
89. M. Widschwendter, J. Berger, H.M. Müller, A.G. Zeimet, and C. Marth Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer J Mammary Gland Biol Neoplasia 6 2001 193 201
90. M. Widschwendter, J. Berger, M. Hermann, H.M. Müller, A. Amberger, M. Zeschnigk, A. Widschwendter, B. Abendstein, A.G. Zeimet, G. Daxenbichler, and C. Marth Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer J Natl Cancer Inst 92 2000 826 832
91. A. Narayan, W. Ji, X.Y. Zhang, A. Marrogi, J.R. Graff, S.B. Baylin, and M. Ehrlich Hypomethylation of pericentromeric DNA in breast adenocarcinomas Int J Cancer 77 1998 833 838
92. A. Eden, F. Gaudet, A. Waghmare, and R. Jaenisch Chromosomal instability and tumors promoted by DNA hypomethylation Science 300 2003 455
93. F. Gaudet, J.G. Hodgson, A. Eden, L. Jackson-Grusby, J. Dausman, J.W. Gray, H. Leonhardt, and R. Jaenisch Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
94. H.G. Russnes, N. Navin, J. Hicks, and A.L. Børresen-Dale Insight into the heterogeneity of breast cancer through next-generation sequencing J Clin Invest 121 2011 3810 3818
95. C. Desmedt, T. Voet, C. Sotiriou, and P.J. Campbell Next-generation sequencing in breast cancer: first take home messages Curr Opin Oncol 24 2012 597 604
96. M. Radovich Next-generation sequencing in breast cancer: translational science and clinical integration Pharmacogenomics 13 2012 637 639